Abiopharma

🔍 International Finance Corp (Executive)

Company: LESAKA TECHNOLOGIES INC (LSAK)

Report Date: 2026-03-26

Detailed Transactions and Holdings:

• Sold 2,468 shares of Common Stock at $4.9508 per share (Direct)
  Date: 2026-03-26 | Code: S | equity_swap_involved: false | shares_owned_after: 5,758,587.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 31,504 shares of Common Stock at $4.91 per share (Direct)
  Date: 2026-03-27 | Code: S | equity_swap_involved: false | shares_owned_after: 5,727,083.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 6,467 shares of Common Stock at $4.9166 per share (Direct)
  Date: 2026-03-30 | Code: S | equity_swap_involved: false | shares_owned_after: 5,720,616.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-26 | Code: H | shares_owned_after: 3,271,862.00

Footnotes:

• F1: Represents the weighted average price of Common Stock sold by IFC African, Latin American and Caribbean Fund, LP ("ALAC"), a United Kingdom limited partnership, of which IFC African, Latin American and Caribbean Fund (GP) LLC, a Delaware limited liability company, serves as general partner, on March 26, 2026, ranging from a low of $4.90 to a high of $5.15. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer to provide full information regarding the number of shares purchased at each separate price.
• F2: Represents the weighted average price of Common Stock sold by ALAC on March 27, 2026, ranging from a low of $4.90 to a high of $4.95. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer to provide full information regarding the number of shares purchased at each separate price.
• F3: Represents the weighted average price of Common Stock sold by ALAC on March 30, 2026, ranging from a low of $4.90 to a high of $4.95. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer to provide full information regarding the number of shares purchased at each separate price.
• F4: The Reporting Person may be deemed to beneficially own shares of Common Stock held indirectly through three funds managed by the Reporting Person that invests third party capital in conjunction with the Reporting Person's investments: (a) ALAC; (b) IFC Financial Institutions Growth Fund, LP, a United Kingdom limited partnership, of which IFC FIG Fund (GP), LLP, a United Kingdom limited liability partnership, serves as general partner; and (c) Africa Capitalization Fund Ltd., a Mauritius limited company primarily engaged in the business of investing in securities.
• F5: The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
• REMARKS: IFC is an international organization established by Articles of Agreement among its member countries, including the United States, and as such, enjoys certain immunities, privileges and exemptions, including the freedom of all of its property and assets from restrictions, regulations, controls and moratoria of any nature. The voluntary provision by IFC of the following information does not in any way constitute or imply a waiver, termination or modification by IFC of any privilege, immunity or exemption of IFC granted in the Articles of Agreement establishing IFC, international conventions, or applicable law.